The slow advent of generic Adderall, due in part to the difficulty inestablishing bioequivalence, will allow the UK company the opportunity toswitch its patients to Adderall XRNew formulations, particularly of methylphenidate-based compounds are setto come to market in high numbers. This can be seen as an attempt toimprove the practicality of the drugs, and therefore the patient compliance
